

- morphism analysis. *J Infect Dis* 1993;168:1052-1055.
2. Tabet SR, Goldbaum GM, Hooton TM, Eisenach KD, Cave MD, Nolan CM. Restriction fragment length polymorphism analysis detecting a community-base tuberculosis outbreak among persons with human immunodeficiency virus. *J Infect Dis* 1994;169:189-192.
 3. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1992;326:1514-1521.
 4. Mathur P, Sacks L, Auten G, Sall R, Levy C, Gordin F. Delayed diagnosis of pulmonary tuberculosis in city hospitals. *Arch Intern Med* 1994;154:306-310.
 5. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Jr, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction length polymorphism. *N Engl J Med* 1992;326:231-235.
 6. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. *N Engl J Med* 1995;332:92-98.
 7. Centers for Disease Control. Guidelines for preventing the transmission of tuberculosis in health care settings with special focus on HIV-related issues. *MMWR* 1990;39(RR-17):1-29.
 8. Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in preventing nosocomial transmission of multi-drug resistant tuberculosis to patients and health care workers. *Ann Intern Med* 1995;122:90-95.
 9. Centers for Disease Control and Prevention. Tuberculosis morbidity—United States, 1996. *MMWR* 1997;46:695-700.
 10. Van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting: recommendations for a standardized methodology. *J Clin Microbiol* 1993;31:406-409.
 11. Genewein A, Telenti A, Bernasconi C, Mordasini C, Weiss S, Maurer A, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. *Lancet* 1993;342:841-844.
 12. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivins B, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. *JAMA* 1996;276:1229-1235.
 13. Bifani PJ, Plikaytis BB, Kapur V, Stockbauer K, Pan X, Lutfey ML, et al. Origin and interstate spread of a New York City multidrug-resistant *Mycobacterium tuberculosis* clone family. *JAMA* 1996;275:452-457.
 14. Plikaytis BB, Marden JL, Crawford JT, Woodley CL, Butler WR, Shinnick TM. Multiplex PCR assay specific for the multidrug-resistant strain W of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1994;32:1542-1546.
 15. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Witam S, et al. Restricted structural gene polymorphism in the *Mycobacterium tuberculosis* complex indicates evolutionarily recent global dissemination. *Proc Natl Acad Sci USA* 1997;94:9869-9874.
 16. van Soolingen D, Qian L, de Haas PEW, Douglas JT, Traore H, Portaels F, et al. Predominance of a single genotype of *Mycobacterium tuberculosis* in countries in East Asia. *J Clin Microbiol* 1995;33:3234-3238.
 17. Ordway DJ, Sonnenberg MG, Donahue SA, Belisle JT, Orme IM. Drug-resistant strains of *Mycobacterium tuberculosis* exhibit a range of virulence for mice. *Infect Immun* 1995;63:741-743.
 18. Valway S, Sanchez M, Shinnick T, Orme I, Agerton T, Onorato I. Extensive transmission of *Mycobacterium tuberculosis* due to increased virulence. In: Program and Abstracts of the Infectious Diseases Society of America, 35th Annual Meeting; San Francisco, CA; September 1997:77.
 19. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. *N Engl J Med* 1994;330:1710-1716.
 20. Ramirez JA, Anderson P, Merp S, Raff MJ. Increased rate of tuberculin skin test conversion among workers at a university hospital. *Infect Control Hosp Epidemiol* 1992;13:579-581.
 21. Tennessee Department of Health. *Annual Report of the Division of Tuberculosis Control for the Year 1992*. Nashville, TN: Tennessee Department of Health; 1994.

Vancomycin-Intermediate *Staphylococcus aureus* in a French Hospital

Gina Pugliese, RN, MS
Martin S. Favero, PhD

Low-level vancomycin resistance was described recently in clinical isolates of methicillin-resistant *Staphylococcus aureus* (MRSA) in Japan and the United States. The first clinical isolate of MRSA with reduced susceptibility to vancomycin has been reported from Limoges, France.

In November 1995, blood cultures and a central line from a 2-year-old girl admitted to hospital for leukemia grew an MRSA strain (LIM-1) that was susceptible to vancomycin (minimum inhibitory concentration [MIC] 2 mg/L. Treatment with vancomycin 35 mg/kg daily and amikacin 15 mg/kg daily for 10 days was not effective. The fever continued, and the patient developed a purulent discharge from the central-line site. Teicoplanin 10 mg/kg daily and amikacin 15 mg/kg was given daily for 18 days. During the first 2 days of

teicoplanin therapy, an *S aureus* strain intermediately resistant to vancomycin (VISA) was isolated from blood cultures. This strain (LIM-2) had stable low-level resistance to vancomycin (MIC=8 mg/L) by the agar dilution method and cross-resistance to teicoplanin (MIC=16 mg/L) and was susceptible only to pristinamycin and trimethoprim-sulfamethoxazole.

Culture of the purulent discharge also yielded a VISA isolate (LIM-3). Teicoplanin plus amikacin was not successful. The fever continued, the patient developed secondary localizations (pleural effusion, subcutaneous abscess), and, 15 days later, blood cultures again grew the VISA strain (LIM-4). Successful treatment consisted of drainage of purulent discharges and administration of the investigational antimicrobial agent quinupristin plus dalbopristin for 10 days. The LIM-2 strain was negative for *vanA*, *vanB*, *vanC1*, *vanC2*, and *vanC3* on polymerase chain

reaction amplification of DNA. Pulse-field gel electrophoresis of *SmaI* restriction digestions from all susceptible and resistant isolates revealed an identical pattern, suggesting that the VISA isolate was selected from the previously vancomycin-susceptible MRSA strain LIM-1.

Emergence of VISA strains generally occurs in patients on multiple courses of vancomycin. For this child, however, neither previous episodes of *S aureus*-associated infections nor vancomycin therapy were reported. This emergence of VISA strains emphasizes the importance of prudent use of antimicrobial and infection control measures to reduce the incidence of VISA strains and to prevent their transmission.

FROM: Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate *Staphylococcus aureus* in a French hospital. *Lancet* 1998;351:1212